The goal of the present study was to determine the efficacy of a novel Ascl2 targeted KISIMA vaccine in stimulating an immune response and inhibiting the formation of colon adenomas in Apc+/Min-FCCC mice. This evidence concerns the gene ASCL2 and colon adenoma.